Regression of Left Ventricular Hypertrophy in Kidney Transplant Recipients: The Potential Role for Inhibition of Mammalian Target of Rapamycin
Regression of Left Ventricular Hypertrophy in Kidney Transplant Recipients: The Potential Role for Inhibition of Mammalian Target of Rapamycin
复制标题
DOI：
10.1016/j.transproceed.2010.07.007
复制
发表时间：
2010-11-01
影响因子：
0.9
通讯作者：
Cannella, G.
中科院分区：
文献类型：
--
作者：
Paoletti, E.;Cannella, G.
在肾移植受者中，高血压治疗，尤其是血管紧张素转换酶(ACE)抑制剂的抗高血压治疗，尤其是血管紧张素转换酶(ACE)抑制剂，被证明至少部分地通过与免疫抑制剂的相互作用而有效地逆转肾移植受者的LVH，从而增加了免疫抑制治疗可能影响受者左室质量(LVM)的可能性。本文主要综述了哺乳动物雷帕霉素靶点(MTOR)抑制在两种实验模型和临床环境中逆转心肌肥厚的潜在作用。我们还讨论了临床研究表明，在肾和心脏移植受者中，从钙调神经磷酸酶抑制剂转换为SRL是有效的，主要是通过减少真正的左室壁肥厚来实现LVH的消退。
Left ventricular hypertrophy (LVH) contributes to elevated cardiac mortality with graft function in renal transplant recipients Antihypertensive therapy, and especially angiotensin-converting enzyme (ACE) inhibitors, proved to be effective in regressing the LVH of renal transplant recipients, at least in part by Interacting with immunosuppressive agents, thus raising the possibility that immunosuppressive therapy might affect changes in the left ventricular mass (LVM) of recipients This review mainly focuses on the potential role of mammalian target of rapamycin (mTOR) inhibition to regress cardiac hypertrophy in both experimental models and in the clinical setting We comment on the results of experimental studies conducted on animal models, which showed regression of cardiac hypertrophy by sirolimus (SRL) We also discuss clinical studies that show that conversion from calcineurin inhibitors to SRL is effective to achieve regression of LVH in both kidney and cardiac transplant recipients, mainly by reducing the true left ventricular wall hypertrophy